Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

ACP Journal Club: review: dipeptidyl peptidase-4 inhibitors do not increase overall adverse events in type 2 diabetes.

Chatterjee S, Chatterjee S.

Ann Intern Med. 2013 Apr 16;158(8):JC8. doi: 10.7326/0003-4819-158-8-201304160-02008. No abstract available.

PMID:
23588773
2.

Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus.

Rosenstock J, Zinman B.

Curr Opin Endocrinol Diabetes Obes. 2007 Apr;14(2):98-107. Review.

PMID:
17940427
3.

Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials.

Madsbad S, Krarup T, Deacon CF, Holst JJ.

Curr Opin Clin Nutr Metab Care. 2008 Jul;11(4):491-9. doi: 10.1097/MCO.0b013e328302f414. Review.

PMID:
18542012
4.

ACP Journal Club. Review: oral phosphodiesterase 4 inhibitors reduce exacerbations but increase adverse events in COPD.

Ram FS.

Ann Intern Med. 2011 Sep 20;155(6):JC3-2. doi: 10.7326/0003-4819-155-6-201109200-02002. No abstract available.

PMID:
21930839
5.

ACP Journal Club. Aliskiren increased adverse events in patients with diabetes and kidney disease who were receiving ACE inhibitors or ARBs.

de Leeuw PW.

Ann Intern Med. 2013 Mar 19;158(6):JC7. doi: 10.7326/0003-4819-158-6-201303190-02007. No abstract available.

PMID:
23552833
6.

Tolerability of dipeptidyl peptidase-4 inhibitors: a review.

Richard KR, Shelburne JS, Kirk JK.

Clin Ther. 2011 Nov;33(11):1609-29. doi: 10.1016/j.clinthera.2011.09.028. Epub 2011 Nov 8. Review.

PMID:
22071236
7.

ACP Journal Club: review: varenicline for tobacco cessation does not increase CV serious adverse events.

Krebs P, Sherman SE.

Ann Intern Med. 2012 Aug 21;157(4):JC2-2. doi: 10.7326/0003-4819-157-4-201208210-02002. No abstract available.

PMID:
22910956
8.

The dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus: cardiovascular safety.

Green JB.

Postgrad Med. 2012 Jul;124(4):54-61. doi: 10.3810/pgm.2012.07.2566. Review.

PMID:
22913894
9.

Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes.

Deacon CF, Holst JJ.

Int J Biochem Cell Biol. 2006;38(5-6):831-44. Epub 2005 Oct 3. Review.

PMID:
16242377
10.

Dipeptidyl peptidase-4 inhibitor for steroid-induced diabetes.

Yanai H, Masui Y, Yoshikawa R, Kunimatsu J, Kaneko H.

World J Diabetes. 2010 Jul 15;1(3):99-100. doi: 10.4239/wjd.v1.i3.99.

11.

Safety of dipeptidyl peptidase 4 inhibitors for treatment of type 2 diabetes.

Mikhail N.

Curr Drug Saf. 2011 Nov 1;6(5):304-9. Review.

PMID:
22424537
12.

ACP Journal Club. Review: DPP-4 inhibitors are less effective than metformin for reducing HbA(1c) in type 2 diabetes.

Chatterjee S.

Ann Intern Med. 2012 Jul 17;157(2):JC2-13. doi: 10.7326/0003-4819-157-2-201207170-02013. No abstract available.

PMID:
22801704
13.

Application of incretin mimetics and dipeptidyl peptidase IV inhibitors in managing type 2 diabetes mellitus.

Boyle PJ, Freeman JS.

J Am Osteopath Assoc. 2007 May;107 Suppl:S10-6. Review.

PMID:
17724013
14.

ACP Journal Club. Review: biologic agents increase short-term risk for some adverse events in conditions other than HIV or AIDS.

Schattner A.

Ann Intern Med. 2012 May 15;156(10):JC5-9. doi: 10.7326/0003-4819-156-10-201205150-02009. No abstract available.

PMID:
22586027
15.
16.

Prolyl peptidases related to dipeptidyl peptidase IV: potential of specific inhibitors in drug discovery.

Van der Veken P, Haemers A, Augustyns K.

Curr Top Med Chem. 2007;7(6):621-35. Review.

PMID:
17352682
17.

[Hypoglycemia in the diabetes treatment - risk minimization with dipeptidyl peptidase-4 inhibitors].

Acuña C.

Drugs Today (Barc). 2010 Dec;46 Suppl F:1-12. Review. Spanish.

PMID:
21240332
18.

ACP Journal Club. Review: Intensive glucose control reduced some CV events but did not change mortality in type 2 diabetes.

Lipscombe LL.

Ann Intern Med. 2009 Sep 15;151(6):JC3-6. No abstract available.

PMID:
19755352
19.

Dipeptidyl peptidase IV inhibitors: therapeutic potential in nonalcoholic fatty liver disease.

Yilmaz Y, Atug O, Yonal O, Duman D, Ozdogan O, Imeryuz N, Kalayci C.

Med Sci Monit. 2009 Apr;15(4):HY1-5.

PMID:
19333209
20.

Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.

Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S.

Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Review.

Items per page

Supplemental Content

Write to the Help Desk